Awarded for year-on-year outstanding international trade performance
Second Queen’s Award for Enterprise following previous award in 2014 in recognition of substantial growth and commercial success
London, UK – 23 April 2019: Ergomed plc, (LSE: ERGO) (‘Ergomed’ or the ‘Company’), a company focused on providing specialised services to the pharmaceutical industry, today announces that PrimeVigilance, its pharmacovigilance, regulatory and medical information service provider, has been awarded the Queen’s Award for Enterprise for the second time reinforcing Ergomed’s broad leadership position as a provider of contract services. Now in its 53rd year, the Queen’s Awards for Enterprise are the most prestigious business awards in the country.
Ergomed’s PrimeVigilance has received the 2019 Queen’s Award for International Trade in recognition of its year-on-year outstanding services in the drug safety sector for its global customer base. As an International Trade winner, PrimeVigilance has demonstrated substantial growth in overseas markets and commercial success, further cementing its place as a global leader in pharmacovigilance.
The global pharmacovigilance market is forecast to grow to more than $8 billion by 2024 from around $3 billion in 2015, with contract outsourcing forecast to expand from around 30% of the market in 2015 to approximately 50% in 2024 (Source: Global Market Insights 2017). It is essential that outstanding companies like Ergomed are able to support these growing markets.
Ergomed’s PrimeVigilance first received a Queen’s Award for Enterprise in 2014 in recognition of its substantial growth and commercial success.
In addition to pharmacovigilance, Ergomed provides full CRO services across all phases of clinical development and therapeutic areas under the Ergomed brand, with a particular focus on orphan drug development.
Dr Miroslav Reljanović, Executive Chairman of Ergomed, commented: “We are delighted that Ergomed’s PrimeVigilance has been honoured with a Queen’s Award for the second time in recent years. This prestigious accolade recognises the Company’s continued year-on-year international growth and reinforces Ergomed’s position as a leading provider of services to the pharmaceutical industry.”
|Ergomed plc||Tel: +44 (0) 1483 402 975|
|Miroslav Reljanović (Executive Chairman)|
|Stuart Jackson (Chief Financial Officer)|
|Numis Securities Limited||Tel: +44 (0) 20 7260 1000|
|Freddie Barnfield (Nominated Adviser)|
|James Black (Broker)|
|Consilium Strategic Communications – for UK enquiries||Tel: +44 (0) 20 3709 5700|
|Chris Gardner / Mary-Jane Elliottemail@example.com|
|Matthew Neal / Olivia Manser|
|MC Services – for Continental European enquiries||Tel: +49 211 5292 5222|
About Ergomed plc
Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed’s fast-growing, profitable services business includes an industry leading suite of specialist pharmacovigilance solutions, integrated under the PrimeVigilance brand, and a full range of high-quality contract research and trial management services under the Ergomed brand (CRO), and an internationally recognised specialist expertise in orphan drug development, under PSR. For further information, visit: http://ergomedplc.com and https://www.primevigilance.com.